8 completed, 2 terminated, 1 unknown. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 8, Terminated 2, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Edaravone: new trials by email Literature Review of Edaravone trials Research Report on Edaravone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 15 | 2022-10-26 | 2026-07-21 |
| Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 202 | 2022-01-11 | 2026-10-21 |
| Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186, Placebo - ALS | Phase 3 | Terminated | Shionogi | 384 | 2020-11-13 | 2026-07-20 |
| Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) MT-1186 - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 124 | 2020-10-29 | 2026-07-20 |
| Safety Study of Oral Edaravone Administered in Subjects With ALS MT-1186 - ALS | Phase 3 | Completed | Shionogi | 185 | 2019-11-18 | 2026-07-21 |
| Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) Edaravone, Riluzole - Neuromuscular Diseases | Phase 2 / Phase 3 | Unknown | Isfahan University of Medical Sciences | 20 | 2017-03-16 | 2019-03-27 |
| Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke Compound Edaravone Injection, Edaravone Injection - Acute Ischemic Stroke | Phase 3 | Completed | Jiangsu Simcere Pharmaceutical Co., Ltd. | 1200 | 2015-05-01 | 2017-01-16 |
| Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis MCI-186, Placebo, MCI-186 in open label phase - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 137 | 2011-12-31 | 2026-07-21 |
| Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) MCI-186, Placebo of MCI-186 - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 181 | 2007-01-31 | 2026-07-21 |
| Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III MCI-186, Placebo of MCI-186 - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 25 | 2006-12-31 | 2026-07-21 |
| Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) MCI-186, Placebo of MCI-186 - Amyotrophic Lateral Sclerosis (ALS) | Phase 3 | Completed | Shionogi | 206 | 2006-05-31 | 2026-07-21 |
Amyotrophic Lateral Sclerosis (6) · Ischemic Stroke (1) · Neuromuscular Diseases (1)
Shionogi (9) · Isfahan University of Medical Sciences (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1)
Japan (7) · Canada (4) · Germany (4) · United States (4) · Italy (3) · France (2) · South Korea (2) · Switzerland (2) · China (1) · Iran (1)
Yongjun Wang, MD (1)
PMID 25286015, PMID 28522181, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 33588596, PMID 36504406, PMID 37525592, PMID 38011420, PMID 40474686, PMID 40485494, PMID 40878665
2019 (1)